Who are CEV chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FEC, SOX Chemotherapy, Consolidation Chemotherapy, PTH followed by dose dense AC of FEC, CVP, Dexamethasona, Idarubicine, ARA-C, Methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cev-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

CEV chemotherapy — Competitive Intelligence Brief

CEV chemotherapy (CEV chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

marketed Combination chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CEV chemotherapy (CEV chemotherapy) — Sun Yat-sen University. CEV is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CEV chemotherapy TARGET	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

Sun Yat-sen University · 5 drugs in this class
Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
University Hospital, Bordeaux · 2 drugs in this class
Beijing Friendship Hospital · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Amgen · 1 drug in this class
Chungnam National University Hospital · 1 drug in this class
AstraZeneca · 1 drug in this class
Children's Cancer Group, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CEV chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/cev-chemotherapy. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab